ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 734,36
0,37%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mustang Bio Inc (MBIO)

  7. Mustang Bio Inc (MBIO) Actualités

MBIO

Mustang Bio (MBIO)

Mustang Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MBIO
DateHeureSourceTitreSymboleSociété
31/05/202423h09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
21/05/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
13/05/202412h01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
02/05/202422h01GlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
30/04/202402h00GlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
28/03/202414h00GlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:MBIOMustang Bio Inc
11/03/202421h05GlobeNewswire Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
11/03/202421h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MBIOMustang Bio Inc
07/03/202413h30GlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:MBIOMustang Bio Inc
11/01/202414h30GlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:MBIOMustang Bio Inc
19/12/202322h06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
12/12/202303h52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
11/12/202314h30GlobeNewswire Inc.Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
14/11/202322h05GlobeNewswire Inc.Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
03/11/202320h22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MBIOMustang Bio Inc
02/11/202314h28GlobeNewswire Inc.Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
30/10/202319h15GlobeNewswire Inc.Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
30/10/202315h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
26/10/202318h30GlobeNewswire Inc.Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
26/10/202315h00GlobeNewswire Inc.Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaNASDAQ:MBIOMustang Bio Inc
14/08/202322h01GlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
14/08/202322h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBIOMustang Bio Inc
07/07/202322h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
30/06/202314h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MBIOMustang Bio Inc
15/05/202322h01GlobeNewswire Inc.Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
28/04/202322h19Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:MBIOMustang Bio Inc
28/04/202322h08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MBIOMustang Bio Inc
14/04/202322h07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MBIOMustang Bio Inc
06/04/202322h07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:MBIOMustang Bio Inc
03/04/202322h50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MBIOMustang Bio Inc
 Showing the most relevant articles for your search:NASDAQ:MBIO

Dernières Valeurs Consultées

USOTC
TRUWY
Trustworths (PK)
NYSE
IDA
IDACORP
USOTC
TNSSF
Transalta (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés